This precipitous sell-off has placed Lilly stock near its lowest levels in six months. Below, I'll explore what's been driving the sell-off, and assess whether Lilly has any catalysts that could make ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...